Moderna has ... version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer improved protection. The booster shot – called ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

Much to the consternation of parents, teachers and cruise ship enthusiasts, there are no approved treatments ... furthest along is Moderna, which has developed a norovirus vaccine with the same ...

Yet, uptake levels of vaccines in the US would tell a different story. As of mid-December, only 20.9 percent of adults in the ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Is the COVID-19 vaccine safe and effective for infants and young children? Here's what parents need to know about vaccinating their babies and toddlers against COVID-19.

The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.

Argentine health authorities Tuesday approved a booster Covid-19 vaccine fully developed in the South American country, it was announced Wednesday in Buenos Aires. The “ARVAC Cecilia Grierson ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to ...

Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks. Announced Friday as ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older.